ELDON BIOLOGICALS A/S — Credit Rating and Financial Key Figures
CVR number: 26747007
Sandtoften 10, 2820 Gentofte
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Fiscal period length | 12 | 12 | 12 | 12 | 12 |
Net sales | |||||
Gross profit | 14 331.40 | 19 531.44 | 16 382.65 | 12 307.39 | 14 865.49 |
Employee benefit expenses | -6 258.14 | -8 031.96 | -6 163.43 | -5 555.69 | -7 407.28 |
Other operating expenses | -15.91 | ||||
Total depreciation | - 406.79 | - 404.11 | - 391.22 | - 405.24 | - 352.66 |
EBIT | 7 666.47 | 11 095.37 | 9 828.00 | 6 346.46 | 7 089.64 |
Other financial income | 1 066.66 | 1 012.16 | 594.31 | 1 096.49 | 1 673.20 |
Other financial expenses | - 256.74 | - 538.11 | -4 376.83 | - 447.56 | - 260.28 |
Net income from associates (fin.) | 142.14 | - 142.14 | |||
Pre-tax profit | 8 476.39 | 11 569.42 | 6 187.62 | 6 853.24 | 8 502.56 |
Income taxes | -1 867.70 | -2 471.00 | -1 215.80 | -1 490.58 | -1 828.92 |
Net earnings | 6 608.69 | 9 098.42 | 4 971.82 | 5 362.66 | 6 673.64 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Development expenditure | 2 786.62 | 5 284.96 | |||
Intangible assets total | 2 786.62 | 5 284.96 | |||
Machinery and equipment | 1 385.00 | 1 173.17 | 781.94 | 462.20 | 170.63 |
Tangible assets total | 1 385.00 | 1 173.17 | 781.94 | 462.20 | 170.63 |
Holdings in group member companies | 142.14 | ||||
Other receivables | 160.80 | 179.10 | 195.87 | 222.15 | 229.83 |
Investments total | 160.80 | 179.10 | 338.01 | 222.15 | 229.83 |
Long term receivables total | |||||
Finished products/goods | 1 974.13 | 2 129.56 | 2 132.49 | 2 850.01 | 3 080.65 |
Advance payments | 17.50 | ||||
Inventories total | 1 974.13 | 2 129.56 | 2 149.99 | 2 850.01 | 3 080.65 |
Current trade debtors | 3 628.93 | 1 947.16 | 2 672.07 | 2 243.04 | 2 147.61 |
Current amounts owed by group member comp. | 12.52 | 1 377.47 | 3 375.47 | 8 633.81 | |
Prepayments and accrued income | 102.45 | 135.73 | 113.17 | 222.64 | 167.00 |
Current other receivables | 244.83 | 42.90 | 350.46 | 384.80 | 537.92 |
Short term receivables total | 3 976.22 | 2 138.30 | 4 513.16 | 6 225.95 | 11 486.34 |
Other current investments | 2 151.39 | 7 137.79 | 2 948.18 | 3 956.87 | 4 616.44 |
Cash and bank deposits | 12 324.03 | 19 588.76 | 24 750.28 | 23 083.83 | 21 844.32 |
Cash and cash equivalents | 14 475.42 | 26 726.54 | 27 698.47 | 27 040.70 | 26 460.76 |
Balance sheet total (assets) | 21 971.57 | 32 346.67 | 35 481.58 | 39 587.63 | 46 713.17 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Share capital | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
Shares repurchased | 500.00 | 500.00 | 500.00 | 1 000.00 | 2 000.00 |
Other reserves | 2 786.62 | 4 735.32 | |||
Retained earnings | 8 940.37 | 15 049.05 | 23 647.47 | 24 832.67 | 26 246.63 |
Profit of the financial year | 6 608.69 | 9 098.42 | 4 971.82 | 5 362.66 | 6 673.64 |
Shareholders equity total | 16 549.06 | 25 147.47 | 29 619.29 | 34 481.95 | 40 155.60 |
Provisions | 153.22 | 148.25 | 139.97 | 162.01 | 693.32 |
Non-current accruals and deferred income | 340.40 | ||||
Non-current liabilities total | 340.40 | ||||
Current loans from credit institutions | 34.43 | ||||
Advances received | 103.89 | ||||
Current trade creditors | 526.88 | 1 159.93 | 1 538.56 | 1 252.62 | 1 215.63 |
Current owed to participating | 1 681.40 | 1 291.99 | 913.90 | 521.93 | 113.98 |
Current owed to group member | 996.18 | 2 021.14 | 4.44 | 633.98 | |
Short-term deferred tax liabilities | 1 221.44 | 1 466.46 | 1 293.35 | ||
Other non-interest bearing current liabilities | 2 064.83 | 2 577.89 | 1 944.53 | 1 663.79 | 2 266.92 |
Current liabilities total | 5 269.30 | 7 050.95 | 5 722.31 | 4 943.66 | 5 523.86 |
Balance sheet total (liabilities) | 21 971.57 | 32 346.67 | 35 481.58 | 39 587.63 | 46 713.17 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.